KIT and gastrointestinal stromal tumor: Preclinical in vitro testing demonstrated superior potency against both primary and secondary KIT mutations compared to imatinib and other approved agents.99 NB003 is currently undergoing phase 1 testing in patients with advanced GIST who progressed on or were intolerant to imatinib and other subsequent-line agents.100